Private Capital Advisors Inc. decreased its position in Eli Lilly and Company (NYSE:LLY) by 1.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 379,334 shares of the company’s stock after selling 5,230 shares during the period. Eli Lilly and accounts for 10.1% of Private Capital Advisors Inc.’s investment portfolio, making the stock its biggest holding. Private Capital Advisors Inc.’s holdings in Eli Lilly and were worth $31,219,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of LLY. Heritage Trust Co purchased a new stake in Eli Lilly and in the 1st quarter valued at about $135,000. Point72 Asia Hong Kong Ltd increased its stake in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. Penserra Capital Management LLC increased its stake in Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the last quarter. American National Bank increased its stake in Eli Lilly and by 5.2% in the 2nd quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after buying an additional 104 shares during the last quarter. Finally, Sandy Spring Bank increased its stake in Eli Lilly and by 51.8% in the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after buying an additional 750 shares during the last quarter. Hedge funds and other institutional investors own 75.72% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.70% on Friday, reaching $83.91. 3,148,723 shares of the company’s stock traded hands. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market cap of $88.53 billion, a price-to-earnings ratio of 36.31 and a beta of 0.34. The firm’s 50-day moving average is $80.84 and its 200-day moving average is $82.02.
Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the company earned $0.86 earnings per share. The firm’s revenue was up 7.8% on a year-over-year basis. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders have sold 590,000 shares of company stock valued at $48,551,300. 0.20% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/09/23/eli-lilly-and-company-lly-is-private-capital-advisors-inc-s-largest-position.html.
Several research firms have commented on LLY. BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC increased their price objective on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up previously from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $88.27.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.